Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIELEN Protect is a dietary supplement developed by Laboratoire Dielen specifically for the management of Irritable Bowel Syndrome (IBS). The product is a combination of L-glutamine, a non-essential amino acid critical for intestinal health, and Gabolysat, a proprietary complex of bioactive marine peptides derived from fish protein hydrolysate. The formulation targets two primary pathophysiological features of IBS: intestinal hyperpermeability (leaky gut) and visceral hypersensitivity. By providing glutamine, the supplement supports the metabolic needs of enterocytes and promotes the expression of tight junction proteins, which are often compromised in IBS patients. The Gabolysat component has demonstrated efficacy in preclinical models for reducing intestinal inflammation and improving barrier integrity. DIELEN Protect is currently being evaluated in clinical trials to assess its impact on IBS severity, quality of life, and gastrointestinal symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DIELEN Protect.